MedTrace Logo

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 271

Last updated 2008-07-17

No results posted yet for this study

Summary

Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Conditions

Interventions

DRUG

adalimumab

40 mg every other week following an 80 mg dose

DRUG

MTX

MTX 7.5 to 25 mg once weekly

DRUG

placebo adalimumab, placebo MTX

placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)

Sponsors & Collaborators

Principal Investigators

  • Global Medical Information · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2006-05-31

Countries

  • United States

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00235820 on ClinicalTrials.gov